Traded Mar 4 · filed 2 days laterNot under a reported trading plan
A United Therapeutics director sold $2.4M of United Therapeutics shares. The filing does not indicate a pre-arranged trading plan.
Traded Feb 5, 2026 · Filed Feb 6, 2026
United Therapeutics's & GENERAL COUNSEL sold $229K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$229,398
Shares × reported transaction price
99 days after results of Oct 29, 2025, 20 days before results of Feb 25, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Traded Mar 4 · filed 2 days laterNot under a reported trading plan
A United Therapeutics director sold $2.4M of United Therapeutics shares. The filing does not indicate a pre-arranged trading plan.
Traded Mar 5 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Paul A Mahon (EVP & GENERAL COUNSEL) sold ~$176K of United Therapeutics
Scheduled in advance